Townsend Adam J. has filed 37 insider transactions across 1 company since January 2023.
Most recent transaction: a sale of 695 shares of Apellis Pharmaceuticals, Inc. ($APLS) on January 29, 2025.
Activity breakdown: 0 open-market purchases and 15 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 29, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 695 | $29.52 | 84,050.0000 | 123,905,000 | 0.82% | 0.00% |
| Jan. 22, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 3323 | $30.43 | 84,745.0000 | 123,905,000 | 3.77% | 0.00% |
| Jan. 17, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 2201 | $29.96 | 88,068.0000 | 123,905,000 | 2.44% | 0.00% |
| Jan. 13, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 2685 | $28.70 | 90,269.0000 | 123,905,000 | 2.89% | 0.00% |
| Feb. 12, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 1148 | $67.77 | 92,453.0000 | 118,678,000 | 1.23% | 0.00% |
| Jan. 29, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 906 | $64.14 | 93,601.0000 | 118,678,000 | 0.96% | 0.00% |
| Jan. 22, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 3413 | $65.00 | 94,507.0000 | 118,678,000 | 3.49% | 0.00% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | A | Common Stock | 23748 | $0.00 | 100,155.0000 | 118,678,000 | 31.08% | 0.02% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 2235 | $66.81 | 97,920.0000 | 118,678,000 | 2.23% | 0.00% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | A | Stock Option (Right to Buy) | 34533 | $66.30 | 34,533.0000 | 118,678,000 | 9999.99% | 0.03% |
| Dec. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Common Stock | 110000 | $15.09 | 186,407.0000 | 106,114,000 | 143.97% | 0.10% |
| Dec. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 67557 | $60.50 | 118,850.0000 | 106,114,000 | 36.24% | 0.06% |
| Dec. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 42443 | $61.31 | 76,407.0000 | 106,114,000 | 35.71% | 0.04% |
| Dec. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Stock Option (Right to Buy) | 110000 | $0.00 | 172,500.0000 | 106,114,000 | 38.94% | 0.10% |
| May 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Common Stock | 5000 | $15.09 | 80,995.0000 | 106,114,000 | 6.58% | 0.00% |
| May 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 5000 | $82.71 | 75,995.0000 | 106,114,000 | 6.17% | 0.00% |
| May 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 282,500.0000 | 106,114,000 | 1.74% | 0.00% |
| April 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Common Stock | 5000 | $15.09 | 80,995.0000 | 106,114,000 | 6.58% | 0.00% |
| April 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 5000 | $74.05 | 75,995.0000 | 106,114,000 | 6.17% | 0.00% |
| April 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 287,500.0000 | 106,114,000 | 1.71% | 0.00% |
| March 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Common Stock | 5000 | $15.09 | 80,995.0000 | 106,114,000 | 6.58% | 0.00% |
| March 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 5000 | $63.84 | 75,995.0000 | 106,114,000 | 6.17% | 0.00% |
| March 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 292,500.0000 | 106,114,000 | 1.68% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | A | Common Stock | 9886 | $0.00 | 77,036.0000 | 106,114,000 | 14.72% | 0.01% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | F | Common Stock | 1041 | $58.50 | 75,995.0000 | 106,114,000 | 1.35% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | A | Stock Option (Right to Buy) | 14023 | $0.00 | 14,023.0000 | 106,114,000 | 9999.99% | 0.01% |
| Feb. 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | F | Common Stock | 782 | $51.21 | 67,150.0000 | 106,114,000 | 1.15% | 0.00% |
| Feb. 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Common Stock | 5000 | $15.09 | 72,932.0000 | 106,114,000 | 7.36% | 0.00% |
| Feb. 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 5000 | $55.85 | 67,932.0000 | 106,114,000 | 6.86% | 0.00% |
| Feb. 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 297,500.0000 | 106,114,000 | 1.65% | 0.00% |
| Jan. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | F | Common Stock | 551 | $52.77 | 67,932.0000 | 106,114,000 | 0.80% | 0.00% |
| Jan. 20, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | F | Common Stock | 1912 | $52.05 | 68,483.0000 | 106,114,000 | 2.72% | 0.00% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | A | Common Stock | 27488 | $0.00 | 70,395.0000 | 106,114,000 | 64.06% | 0.03% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | A | Stock Option (Right to Buy) | 43183 | $52.66 | 43,183.0000 | 106,114,000 | 9999.99% | 0.04% |
| Jan. 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Common Stock | 5000 | $15.09 | 47,907.0000 | 106,114,000 | 11.65% | 0.00% |
| Jan. 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | S | Common Stock | 5000 | $50.70 | 42,907.0000 | 106,114,000 | 10.44% | 0.00% |
| Jan. 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Townsend Adam J. | Chief Commercial Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 302,500.0000 | 106,114,000 | 1.63% | 0.00% |